<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="597">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05379348</url>
  </required_header>
  <id_info>
    <org_study_id>1811673</org_study_id>
    <nct_id>NCT05379348</nct_id>
  </id_info>
  <brief_title>Davos Alzheimer's Collaborative Study: Sequential Administration of Digital Testing To Screen For Cognitive Impairment Followed By Blood Based Biomarkers To Assist With Timely Detection And Accurate Diagnosis Of Alzheimer's Disease</brief_title>
  <acronym>DAC</acronym>
  <official_title>Davos Alzheimer's Collaborative Study: Sequential Administration of Digital Testing To Screen For Cognitive Impairment Followed By Blood Based Biomarkers To Assist With Timely Detection And Accurate Diagnosis Of Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AdventHealth Translational Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Davos Alzheimer's Collaborative</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AdventHealth Translational Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate how we can detect Alzheimer's disease early by&#xD;
      using an online memory test and a simple blood test. These new methods for early diagnosis&#xD;
      could allow people to begin treatment sooner, with the potential to improve the lives of&#xD;
      millions of people.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2022</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quantify the proportion of individuals at least 65 years old with cognitive impairment</measure>
    <time_frame>Less than 6 months</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">16000</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>General study participants (patients)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthcare Practitioners</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-Program Chart Audits (100 patients what will be chart audited)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cognitive Assessment</intervention_name>
    <description>Montreal Cognitive Assessment - MoCA, which is a cognitive screening tool that assesses: memory, concentration, language, and orientation to time and place. this written cognitive test should take no more than 20 minutes.</description>
    <arm_group_label>General study participants (patients)</arm_group_label>
    <other_name>MoCA</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy male and females ages &gt;65 years old.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Subjects must meet the following criteria for entry into the study:&#xD;
&#xD;
          1. Male or female &gt; 65 years of age at the time of consent;&#xD;
&#xD;
          2. Understand and voluntarily sign an informed consent form;&#xD;
&#xD;
        Inclusion criteria is assessed at both e-consent (assessed by participant's self-reporting&#xD;
        of age and understanding) and in-person consent at TRI (assessed by clinical research&#xD;
        coordinators in TRI).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Subjects who meet any of the following criteria will not be eligible for entry into the&#xD;
        study:&#xD;
&#xD;
          1. Subjects who are unable to hear and see well enough to complete the assessments;&#xD;
&#xD;
          2. Prior diagnosis of dementia or Alzheimer's disease documented in their medical record&#xD;
             and/or as diagnosed by a physician; Exclusion criteria is assessed by by participant's&#xD;
             self-reporting of understanding and not having a prior diagnosis of dementia at the&#xD;
             time of e-consentand visit 1 at TRI. ).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study PI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruitment Department</last_name>
    <phone>407-303-7100</phone>
    <email>Fh.tri.recruitment@adventhealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AdventHealth Translational Research Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Recruitment Department</last_name>
      <phone>407-303-7100</phone>
      <email>Fh.tri.recruitment@adventhealth.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.adventhealthresearchinstitute.com/research/translational-research</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2022</verification_date>
  <study_first_submitted>May 13, 2022</study_first_submitted>
  <study_first_submitted_qc>May 17, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2022</study_first_posted>
  <last_update_submitted>May 17, 2022</last_update_submitted>
  <last_update_submitted_qc>May 17, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

